"","Column1","study","year","psy_or_med","active_type","control_type","instrument","primary","hierarchy","rating","baseline_mean_active","baseline_sd_active","baseline_n_active","baseline_mean_control","baseline_sd_control","baseline_n_control","post_mean_active","post_sd_active","post_n_active","post_mean_control","post_sd_control","post_n_control","active_mean_change","active_sd_change","active_n_change","control_mean_change","control_sd_change","control_n_change","response_criterion","observed_responders_active","observed_responders_active_n","observed_resp_rate_active","observed_responders_control","observed_responders_control_n","observed_resp_rate_control","time","time_weeks","comorbid_mental","comorbid_mental?","country","age_group","age_m_active","age_sd_active","age_m_control","age_sd_control","age_m_overall","age_sd_overall","active_percent_women","control_percent_women","diagnosis","no_sites","Notes","responders_active","responders_control","responders_active_30","responders_control_30","responders_active_35","responders_control_35"
"1",1,"Organon","2002a",0,"Mirtazapine","Placebo","CDRS",1,1,"clinician",NA,NA,82,NA,NA,44,35.08,NA,82,37.24,NA,44,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,"post",8,"n","NA",NA,"7 to 17",12.3,NA,12.4,NA,NA,NA,47.6,56.8,"mdd","17",NA,NA,NA,NA,NA,NA,NA
"2",2,"Organon","2002b",0,"Mirtazapine","Placebo","CDRS",1,1,"clinician",NA,NA,88,NA,NA,45,35.39,NA,82,38.76,NA,41,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,"post",8,"n","NA",NA,"7 to 17",11.9,NA,12.3,NA,NA,NA,50,50.5,"mdd","15",NA,NA,NA,NA,NA,NA,NA
"3",3,"Atkinson","2014",0,"Duloxetine","Placebo","CDRS-R",1,1,"clinician",59.2,10.5,117,60.2,11.7,103,35,NA,87,35,NA,87,NA,NA,NA,NA,NA,NA,"50% improvement on CDRS",NA,NA,0.67,NA,NA,0.62,"post",10,"n","NA","USA","7 to 17",13.1,3,13.3,3.1,NA,NA,54.7,49.5,"mdd","65",NA,NA,NA,NA,NA,NA,NA
"4",4,"Atkinson","2014",0,"Fluoxetine","Placebo","CDRS-R",1,1,"clinician",58.8,10.6,117,60.2,11.7,103,35.6,NA,91,35,NA,87,NA,NA,NA,NA,NA,NA,"50% improvement on CDRS",NA,NA,0.63,NA,NA,0.62,"post",10,"n","NA","USA","7 to 17",13.1,3.3,13.3,3.1,NA,NA,52.1,49.5,"mdd","65",NA,NA,NA,NA,NA,NA,NA
"5",5,"Berard","2006",0,"Paroxetine","Placebo","MADRS",1,1,"clinician",25.9,6.75,182,25.9,5.79,93,NA,NA,177,NA,NA,177,-13.6,10.91,177,-12.8,10.3,91,"50% improvement from baseline",107,177,NA,53,91,NA,"post",12,"y","Anxiety disorders (specific phobia, separation anxiety disorder, panic disorder, social phobia, GAD) and ADHD","International (Belgium, Italy, Spain, UK< The Netherlands, Canada, South Africa, UAE, Argentina, Mexico)","12 to 19",15.5,1.6,15.8,1.6,NA,NA,67,67,"mdd","33",NA,NA,NA,NA,NA,NA,NA
"6",6,"Berard","2006",0,"Paroxetine","Placebo","K-SADS-L",1,0,"clinician",NA,NA,182,NA,NA,93,NA,NA,171,NA,NA,88,-9.33,7.06,171,-8.92,6.57,88,NA,NA,NA,NA,NA,NA,NA,"post",12,"y","Anxiety disorders (specific phobia, separation anxiety disorder, panic disorder, social phobia, GAD) and ADHD","International (Belgium, Italy, Spain, UK< The Netherlands, Canada, South Africa, UAE, Argentina, Mexico)","12 to 19",15.5,1.6,15.8,1.6,NA,NA,67,67,"mdd","33",NA,NA,NA,NA,NA,NA,NA
"7",7,"Berard","2006",0,"Paroxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",119,172,NA,51,89,NA,"post",12,"y","Anxiety disorders (specific phobia, separation anxiety disorder, panic disorder, social phobia, GAD) and ADHD","International (Belgium, Italy, Spain, UK< The Netherlands, Canada, South Africa, UAE, Argentina, Mexico)","12 to 19",15.5,1.6,15.8,1.6,NA,NA,67,67,"mdd","33",NA,NA,NA,NA,NA,NA,NA
"8",8,"Berard","2006",0,"Paroxetine","Placebo","BDI",0,0,"clinician",23,10.79,182,22.4,11.57,93,NA,NA,174,NA,NA,174,-12.5,10.82,174,-12.07,10.25,90,"Change from baseline BDI score.",NA,NA,NA,NA,NA,NA,"post",12,"y","Anxiety disorders (specific phobia, separation anxiety disorder, panic disorder, social phobia, GAD) and ADHD","International (Belgium, Italy, Spain, UK< The Netherlands, Canada, South Africa, UAE, Argentina, Mexico)","12 to 19",15.5,1.6,15.8,1.6,NA,NA,67,67,"mdd","33",NA,NA,NA,NA,NA,NA,NA
"9",9,"Bristol-Myers Squibb","2002a",0,"Nefazodone","Placebo","CDRS",1,1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,-25.8,NA,NA,-22.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","15",NA,NA,NA,NA,NA,NA,NA
"10",10,"Bristol-Myers Squibb","2002a",0,"Nefazodone","Placebo","HAM-D",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,-9.9,NA,NA,-8,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","15",NA,NA,NA,NA,NA,NA,NA
"11",11,"Bristol-Myers Squibb","2002a",0,"Nefazodone","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",NA,NA,0.63,NA,NA,0.44,"post",8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","15",NA,NA,NA,NA,NA,NA,NA
"12",12,"Bristol-Myers Squibb","2002b",0,"Nefazodone","Placebo","CDRS",1,1,"clinician",61.2,NA,90,58.3,NA,93,NA,NA,NA,NA,NA,NA,-23.2,NA,90,-21.6,NA,93,"missing",NA,NA,NA,NA,NA,NA,"post",8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","15",NA,NA,NA,NA,NA,NA,NA
"13",13,"Emslie","1997",0,"Fluoxetine","Placebo","CDRS",1,1,"clinician",58.5,10.5,48,57.6,10.4,48,38.4,14.8,34,47.1,17,26,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",8,"y","Dysthymia, anxiety disordes, ADHD, oppositional/conduct disorder","USA","7 to 17",12.2,2.7,12.5,2.6,NA,NA,46,46,"mdd","1",NA,13,4,18,10,16,5
"14",14,"Emslie","1997",0,"Fluoxetine","Placebo","CDI/BDI *",0,0,"clinician",15.8,10.6,48,15.3,11.9,48,9.9,12,34,11.2,10.8,26,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",8,"y","Dysthymia, anxiety disordes, ADHD, oppositional/conduct disorder","USA","7 to 17",12.2,2.7,12.5,2.6,NA,NA,46,46,"mdd","1",NA,10,12,17,15,17,10
"15",15,"Emslie","1997",0,"Fluoxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",27,48,NA,16,48,NA,"post",8,"y","Dysthymia, anxiety disordes, ADHD, oppositional/conduct disorder","USA","7 to 17",12.2,2.7,12.5,2.6,NA,NA,46,46,"mdd","1",NA,NA,NA,NA,NA,NA,NA
"16",16,"Emslie","2002a",0,"Fluoxetine","Placebo","CDRS",1,1,"clinician",57.1,9.9,109,55.1,11.8,110,35.1,13.5,109,40.2,13.5,105,NA,NA,NA,NA,NA,NA,"30% improvement in CDRS",71,109,NA,54,101,NA,"post",9,"y","ADHD, oppositional defiant disorder, conduct disorder","USA","8 to 17",12.7,2.46,12.69,2.67,NA,NA,49.5,49.5,"mdd","15",NA,29,15,64,49,63,39
"17",17,"Emslie","2002a",0,"Fluoxetine","Placebo","MADRS",0,0,"clinician",21.6,7.5,109,21.5,8.3,110,11.2,9,109,13.9,8.2,105,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",9,"y","ADHD, oppositional defiant disorder, conduct disorder","USA","8 to 17",12.7,2.46,12.69,2.67,NA,NA,49.5,49.5,"mdd","15",NA,52,30,75,60,71,55
"18",18,"Emslie","2002a",0,"Fluoxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",57,109,0.523,NA,NA,0.368,"post",9,"y","ADHD, oppositional defiant disorder, conduct disorder","USA","8 to 17",12.7,2.46,12.69,2.67,NA,NA,49.5,49.5,"mdd","15",NA,NA,NA,NA,NA,NA,NA
"19",19,"Emslie","2002b",0,"Nefazodone","Placebo","CDRS",1,1,"clinician",NA,NA,99,NA,NA,96,NA,NA,99,NA,NA,96,-26.5,NA,99,-22.5,NA,96,NA,NA,NA,NA,NA,NA,NA,"post",8,"missing","NA","USA","12 to 17",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","missing",NA,NA,NA,NA,NA,NA,NA
"20",20,"Emslie","2002b",0,"Nefazodone","Placebo","HAM-D",1,1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,-10,NA,99,-8.2,NA,96,NA,NA,NA,NA,NA,NA,NA,"post",8,"missing","NA","USA","12 to 17",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","missing",NA,NA,NA,NA,NA,NA,NA
"21",21,"Emslie","2002b",0,"Nefazodone","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",61,99,NA,40,96,NA,"post",8,"missing","NA","USA","12 to 17",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","missing",NA,NA,NA,NA,NA,NA,NA
"22",22,"Emslie","2006",0,"Paroxetine","Placebo","CDRS",1,1,"clinician",60.7,9.37,101,62.6,8.96,102,NA,NA,101,NA,NA,100,-22.58,14.77,101,-23.38,16,100,NA,NA,NA,NA,NA,NA,NA,"post",8,"y","adhd","USA + Canada","7 to 17",11.9,3,12.1,2.95,12,2.97,46.8,46.8,"mdd","40",NA,NA,NA,NA,NA,NA,NA
"23",23,"Emslie","2006",0,"Paroxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",49,101,NA,46,100,NA,"post",8,"y","adhd","USA + Canada","7 to 17",11.9,3,12.1,2.95,12,2.97,46.8,46.8,"mdd","40",NA,NA,NA,NA,NA,NA,NA
"24",24,"Emslie","2007a",0,"Venlafaxine","Placebo","CDRS",1,1,"clinician",54.4,NA,80,54.4,NA,85,36.3,13.19,68,38.3,12.82,73,NA,NA,NA,NA,NA,NA,"35% improvement from baseline score",43,68,NA,37,73,NA,"post",8,"n","NA","USA","7 to 17",NA,2.6,NA,2.6,NA,NA,NA,NA,"mdd","50",NA,22,13,44,36,27,24
"25",25,"Emslie","2007b",0,"Venlafaxine","Placebo","CDRS",1,1,"clinician",57.3,NA,102,57.3,NA,94,32.7,13.06,101,34.5,13.43,92,NA,NA,NA,NA,NA,NA,"35% improvement from baseline score",77,101,NA,62,92,NA,"post",8,"n","NA","USA","7 to 17",NA,2.6,NA,2.6,NA,NA,NA,NA,"mdd","50",NA,30,29,70,67,72,51
"26",26,"Emslie","2007 (combined)",0,"Venlafaxine","Placebo","MADRS",0,0,"clinician",25.6,6.6,168,25.1,6.1,169,NA,NA,160,NA,NA,161,NA,NA,NA,NA,NA,NA,"50% improvement from baseline score",81,160,NA,75,161,NA,"post",8,"n","NA","USA","7 to 17",12.2,2.6,12.3,2.6,NA,NA,44,47,"mdd","50",NA,NA,NA,NA,NA,NA,NA
"27",27,"Emslie","2007 (combined)",0,"Venlafaxine","Placebo","HAM-D",0,0,"clinician",18.2,5.6,168,18.1,5.6,169,NA,NA,166,NA,NA,162,NA,NA,NA,NA,NA,NA,"50% improvement from baseline score",85,166,NA,79,162,NA,"post",8,"n","NA","USA","7 to 17",12.2,2.6,12.3,2.6,NA,NA,44,47,"mdd","50",NA,NA,NA,NA,NA,NA,NA
"28",28,"Emslie","2009",0,"Escitalopram","Placebo","CDRS",1,1,"clinician",57.6,8.19,154,56,8.27,157,NA,NA,NA,NA,NA,NA,-22.1,15.14,154,-18.8,15.91,157,"40% improvement from baseline score",91,154,NA,76,157,NA,"post",8,"y","ADHD, enuresis, GAD","USA","12 to 17",14.7,1.6,14.5,1.5,NA,NA,59.4,58.6,"mdd","40",NA,NA,NA,NA,NA,NA,NA
"29",29,"Emslie","2009",0,"Escitalopram","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",99,154,NA,83,157,NA,"post",8,"y","ADHD, enuresis, GAD","USA","12 to 17",14.7,1.6,14.5,1.5,NA,NA,59.4,58.6,"mdd","40",NA,NA,NA,NA,NA,NA,NA
"30",30,"Emslie","2014",0,"Duloxetine","Placebo","CDRS",1,1,"clinician",59.3,10.9,108,58.2,9.4,122,35,NA,105,37.4,NA,117,-23.9,NA,105,-21.6,NA,117,"50% improvement from baseline scores",NA,NA,0.69,NA,NA,0.6,"post",10,"n","NA","USA, Mexico, Canada, Argentina","7 to 17",12.9,2.9,13.1,2.9,NA,NA,55.6,56.6,"mdd","60",NA,NA,NA,NA,NA,NA,NA
"31",31,"Emslie","2014",0,"Duloxetine","Placebo","CDRS",1,1,"clinician",59.8,11,116,58.2,9.4,122,34.4,NA,114,37.4,NA,117,-24.6,NA,114,-21.6,NA,117,"50% improvement from baseline scores",NA,NA,0.69,NA,NA,0.6,"post",10,"n","NA","USA, Mexico, Canada, Argentina","7 to 17",12.9,2.9,13.1,2.9,NA,NA,40.5,56.6,"mdd","60",NA,NA,NA,NA,NA,NA,NA
"32",32,"Emslie","2014",0,"Fluoxetine","Placebo","CDRS",1,1,"clinician",57.9,10.1,117,58.2,9.4,122,36.4,NA,112,37.4,NA,117,-22.6,NA,112,-21.6,NA,117,"50% improvement from baseline scores",NA,NA,0.61,NA,NA,0.6,"post",10,"n","NA","USA, Mexico, Canada, Argentina","7 to 17",13,3.2,13.1,2.9,NA,NA,52.1,56.6,"mdd","60",NA,NA,NA,NA,NA,NA,NA
"33",33,"Findling","2009",0,"Fluoxetine","Placebo","CDRS",1,1,"clinician",53,9.84,18,53.94,9.84,16,34.6,13.66,18,31.31,13.68,16,-18.4,12.47,18,-22.63,12.48,16,"30% improvement from baseline",NA,NA,0.72,NA,16,0.81,"post",8,"y","Substance-related disorder, ADHD, PTSD, conduct disorder","USA","12 to 17",16.55,1.11,16.35,1.08,16.46,1.08,22,6,"mdd","1",NA,5,9,10,11,12,9
"34",34,"Findling","2009",0,"Fluoxetine","Placebo","BDI",0,0,"self-report",17.2,13.15,18,13,13.32,16,7.62,7.59,15,8.12,7.61,13,-9.58,12.74,15,-4.88,12.76,13,NA,NA,NA,NA,NA,NA,NA,"post",8,"y","Substance-related disorder, ADHD, PTSD, conduct disorder","USA","12 to 17",16.55,1.11,16.35,1.08,16.46,1.08,22,6,"mdd","1",NA,7,8,11,10,13,9
"35",35,"Findling","2009",0,"Fluoxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",9,18,NA,6,16,NA,"post",8,"y","Substance-related disorder, ADHD, PTSD, conduct disorder","USA","12 to 17",16.55,1.11,16.35,1.08,16.46,1.08,22,6,"mdd","1",NA,NA,NA,NA,NA,NA,NA
"36",36,"Geller","1990",0,"Nortriptyline","Placebo","GAS",0,0,"clinician",37.6,3.8,12,38.6,3.9,19,54.2,14.9,12,48.9,16.2,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",8,"y","Melancholia, separation anxiety, antisocial behaviour","USA","12 to 17",14,1.7,14.4,1.6,14.3,1.5,75,42.1,"mdd","missing",NA,0,1,0,1,1,1
"37",37,"Geller","1990",0,"Nortriptyline","Placebo","CDRS",1,1,"clinician",51.3,4.4,12,52.4,3.7,19,34.7,7.8,12,37.8,9.1,19,NA,NA,NA,NA,NA,NA,"CDRS score of ≤25",1,12,NA,4,19,NA,"post",8,"y","Melancholia, separation anxiety, antisocial behaviour","USA","12 to 17",14,1.7,14.4,1.6,14.3,1.5,75,42.1,"mdd","missing",NA,2,1,7,9,5,4
"38",38,"Geller","1992",0,"Nortriptyline","Placebo","CDRS",1,1,"clinician",49.9,4.2,26,49.6,4.6,24,32.9,11.4,26,32,9.8,24,NA,NA,NA,NA,NA,NA,"CDRS score of ≤20",8,26,NA,4,24,NA,"post",8,"n","NA","USA","6 to 12",9.7,1.6,9.7,1.7,9.7,1.6,26.9,33.3,"mdd","missing",NA,6,3,17,13,14,9
"39",39,"Geller","1992",0,"Nortriptyline","Placebo","K-SADS-L",0,0,"clinician",3.98,0.42,26,3.89,0.5,24,2.41,0.81,26,2.2,0.78,24,NA,NA,NA,NA,NA,NA,"Scores of 1 or 2 on all MDD items on the K-SADS",12,26,NA,14,24,NA,"post",8,"n","NA","USA","6 to 12",9.7,1.6,9.7,1.7,9.7,1.6,26.9,33.3,"mdd","missing",NA,7,8,18,19,15,16
"40",40,"Hughes","1990",0,"Imipramine","Placebo","CDRS",1,1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"50% reduction in CDRS",4,7,NA,1,5,NA,"post",6,"y","Anxiety-related disorders (Group1) and Conduct or oppositional disorders (group2)",NA,"6 to 12",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","missing",NA,NA,NA,NA,NA,NA,NA
"41",41,"Hughes","1990",0,"Imipramine","Placebo","CDRS",1,1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"50% reduction in CDRS",2,6,NA,6,9,NA,"post",6,"y","Anxiety-related disorders (Group1) and Conduct or oppositional disorders (group2)",NA,"6 to 12",NA,NA,NA,NA,NA,NA,NA,NA,"mdd","missing",NA,NA,NA,NA,NA,NA,NA
"42",42,"Keller","2001",0,"Paroxetine","Placebo","HAM-D",1,1,"clinician",18.98,4.15,93,18.97,4.1,87,8.24,7.68,90,9.88,7.74,87,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",60,90,NA,48,87,NA,"post",8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",14.8,1.6,15.1,1.6,NA,NA,62.4,65.5,"mdd","12",NA,55,46,67,58,57,49
"43",43,"Keller","2001",0,"Paroxetine","Placebo","K-SADS-L",0,0,"clinician",28.25,5.01,93,28.84,4.85,87,16.59,7.65,83,19.27,7.65,85,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",14.8,1.6,15.1,1.6,NA,NA,62.4,65.5,"mdd","12",NA,32,21,56,45,53,28
"44",44,"Keller","2001",0,"Paroxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",59,90,NA,42,87,NA,"post",8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",14.8,1.6,15.1,1.6,NA,NA,62.4,65.5,"mdd","12",NA,NA,NA,NA,NA,NA,NA
"45",45,"Keller","2001",0,"Imipramine","Placebo","HAM-D",1,1,"clinician",18.11,4.19,95,18.97,4.1,87,9.2,7.85,94,9.88,7.74,87,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",55,94,NA,48,87,NA,"post",8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",14.9,1.6,15.1,1.6,NA,NA,58.9,65.5,"mdd","12",NA,46,38,64,60,60,67
"46",46,"Keller","2001",0,"Imipramine","Placebo","K-SADS-L",0,0,"clinician",27.54,4.97,95,28.84,4.85,87,17.99,7.79,88,19.27,7.65,85,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",14.9,1.6,15.1,1.6,NA,NA,58.9,65.5,"mdd","12",NA,30,19,44,41,46,33
"47",47,"Keller","2001",0,"Imipramine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",49,94,NA,42,87,NA,"post",8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",14.9,1.6,15.1,1.6,NA,NA,58.9,65.5,"mdd","12",NA,NA,NA,NA,NA,NA,NA
"48",48,"Klein","1998",0,"Desipramine","Placebo","HAM-D",1,1,"clinician",21.44,3.7,23,21.33,5.2,22,10.23,2.1,18,14.61,2.1,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",6,"y","Anxiety disorders and behaviour disorders","USA","13 to 18",NA,NA,NA,NA,15.66,1.43,67,67,"mdd","missing",NA,8,0,18,10,18,9
"49",49,"Klein","1998",0,"Desipramine","Placebo","BDI",0,0,"clinician",24.62,9.4,23,21.57,11.1,22,12,9.6,16,15.92,9.6,14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",6,"y","Anxiety disorders and behaviour disorders","USA","13 to 18",NA,NA,NA,NA,15.66,1.43,67,67,"mdd","missing",NA,10,4,12,4,12,5
"50",50,"Klein","1998",0,"Desipramine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",12,18,NA,9,18,NA,"post",6,"y","Anxiety disorders and behaviour disorders","USA","13 to 18",NA,NA,NA,NA,15.66,1.43,67,67,"mdd","missing",NA,NA,NA,NA,NA,NA,NA
"51",51,"Kutcher","1994",0,"Desipramine","Placebo","HAM-D",1,1,"clinician",22.63,5.17,30,23.77,5.31,30,12.68,8.68,17,13.42,8.43,25,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",NA,NA,0.48,NA,NA,0.35,"post",6,"n","NA","Canada","15 to 20",NA,NA,NA,NA,17.8,NA,70,70,"mdd","missing",NA,9,7,11,14,14,16
"52",52,"Kutcher","1994",0,"Desipramine","Placebo","HAM-D",1,1,"clinician",22.63,5.17,30,23.77,5.31,30,12.68,8.68,17,13.42,8.43,25,NA,NA,NA,NA,NA,NA,"Dichotomous outcome variable (well/ill). Final HAM-D score of 7 or less indicated well",NA,NA,0.28,NA,NA,NA,"post",6,"n","NA","Canada","15 to 20",NA,NA,NA,NA,17.8,NA,70,70,"mdd","missing",NA,7,13,10,18,7,13
"53",53,"Kutcher","1994",0,"Desipramine","Placebo","BDI",0,0,"self-report",NA,NA,30,NA,NA,30,13.3,NA,17,17.2,NA,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",6,"n","NA","Canada","15 to 20",NA,NA,NA,NA,17.8,NA,70,70,"mdd","missing",NA,NA,NA,NA,NA,NA,NA
"54",54,"Kye","1996",0,"Amitriptyline","Placebo","K-SADS-L",1,0,"clinician",20.7,4.3,18,18.7,2.2,13,15.7,5.3,12,15.6,4.7,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",8,"n","NA","USA","12 to 17",14.6,1.8,15.1,2.1,NA,NA,27.7,30.8,"mdd","missing",NA,2,1,6,4,5,4
"55",55,"Kye","1996",0,"Amitriptyline","Placebo","HAM-D",1,1,"clinician",12,4.5,18,13.2,4.1,13,8,4.9,12,8.8,4.5,10,NA,NA,NA,NA,NA,NA,"50% improvement",13,18,NA,11,13,NA,"post",8,"n","NA","USA","12 to 17",14.6,1.8,15.1,2.1,NA,NA,27.7,30.8,"mdd","missing",NA,7,4,7,9,9,4
"56",56,"March","2004",0,"Fluoxetine","Placebo","CDRS",1,1,"clinician",58.94,4,109,61.18,4.27,112,36.3,8.18,109,41.77,7.99,112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",12,"y","Anxiety, disruptive behaviour, obsessive-compulsice/tic, substance use, attention-deficit/hyperactivity","USA","12 to 17",NA,NA,NA,NA,14.6,1.5,54.4,54.4,"mdd","13",NA,17,12,73,53,71,50
"57",57,"March","2004",0,"Fluoxetine","Placebo","RADS",1,0,"clinician",76.96,9.57,109,81.26,9.22,112,60.58,13.07,109,66.68,11.41,112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"post",12,"y","Anxiety, disruptive behaviour, obsessive-compulsice/tic, substance use, attention-deficit/hyperactivity","USA","12 to 17",NA,NA,NA,NA,14.6,1.5,54.4,54.4,"mdd","13",NA,7,0,32,21,22,8
"58",58,"March","2004",0,"Fluoxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",66,109,NA,39,112,NA,"post",12,"y","Anxiety, disruptive behaviour, obsessive-compulsice/tic, substance use, attention-deficit/hyperactivity","USA","12 to 17",NA,NA,NA,NA,14.6,1.5,54.4,54.4,"mdd","13",NA,NA,NA,NA,NA,NA,NA
"59",59,"Paxil (GlaxoSmithKline)","2009",0,"Paroxetine","Placebo","CDRS",1,1,"clinician",NA,NA,29,NA,NA,27,NA,NA,29,NA,NA,27,-16.5,13.19,29,-11.9,13.2,27,NA,NA,NA,NA,NA,NA,NA,"post",8,"n","NA","Japan","7 to 17",14.4,1.99,14.8,2.62,NA,NA,55.2,66.7,"mdd","33",NA,NA,NA,NA,NA,NA,NA
"60",60,"Paxil (GlaxoSmithKline)","2009",0,"Paroxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",15,29,NA,11,27,NA,"post",8,"n","NA","Japan","7 to 17",14.4,1.99,14.8,2.62,NA,NA,55.2,66.7,"mdd","33",NA,NA,NA,NA,NA,NA,NA
"61",61,"Puig-Antich","1987",0,"Imipramine","Placebo","K-SADS-L",1,1,"clinician",3.1,0.43,20,3,0.66,22,1.9,0.68,16,1.9,0.86,22,NA,NA,NA,NA,NA,NA,"Responder: if K-SADS scores in both depressed mood and anhedonia were ≤2. Non-responder: if K-SADS score for at least one of these two key items were ≥3.",9,16,NA,15,22,NA,"post",5,"n","NA","USA","missing",9.03,1.58,9.18,1.28,NA,NA,62.5,59,"mdd","33",NA,6,7,11,13,8,11
"62",62,"Von Knorring","2006",0,"Citalopram","Placebo","K-SADS-L",1,0,"clinician",32,5,124,32,5,120,NA,NA,79,NA,NA,74,NA,NA,NA,NA,NA,NA,"K-SADS depression and anhedonia scores ≤2",NA,NA,0.6,NA,NA,0.61,"post",12,"n","NA","European, multi-centered (31 recruitment sites)","13 to 18",16,1,16,1,16,1,NA,NA,"mdd","31",NA,NA,NA,NA,NA,NA,NA
"63",63,"Von Knorring","2006",0,"Citalopram","Placebo","MADRS",1,1,"clinician",30,5.5,124,30,5.5,120,NA,NA,79,NA,NA,74,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",NA,NA,0.61,NA,NA,0.59,"post",12,"n","NA","European, multi-centered (31 recruitment sites)","13 to 18",16,1,16,1,16,1,NA,NA,"mdd","31",NA,NA,NA,NA,NA,NA,NA
"64",64,"Wagner","2003",0,"Sertraline","Placebo","CDRS",1,1,"clinician",64.3,11,189,64.6,11,187,NA,NA,185,NA,NA,179,-22.84,NA,NA,-20.19,NA,NA,"40% improvement",128,185,NA,106,179,NA,"post",10,"y","Most common were oppositional defiant disorder, anxiety, adjustment reaction and phobic disorders.","International (USA, India, Canada, Costa Rica, Mexico)","6 to 17",NA,NA,NA,NA,NA,NA,57.1,44.9,"mdd","53",NA,NA,NA,NA,NA,NA,NA
"65",65,"Wagner","2003",0,"Sertraline","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",117,185,NA,95,179,NA,"post",10,"y","Most common were oppositional defiant disorder, anxiety, adjustment reaction and phobic disorders.","International (USA, India, Canada, Costa Rica, Mexico)","7 to 17",NA,NA,NA,NA,NA,NA,57.1,44.9,"mdd","53",NA,NA,NA,NA,NA,NA,NA
"66",66,"Wagner","2004",0,"Citalopram","Placebo","CDRS",1,1,"clinician",58.8,10.9,89,57.8,11.1,85,NA,NA,89,NA,NA,85,NA,NA,NA,NA,NA,NA,"CDRS score ≤28",32,89,NA,20,85,NA,"post",8,"y","Dysthmia, enuresis","USA","7 to 17",12.1,3.1,12.1,2.8,12.1,NA,52.8,54.1,"mdd","21",NA,NA,NA,NA,NA,NA,NA
"67",67,"Wagner","2004",0,"Citalopram","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",42,89,NA,38,85,NA,"post",8,"y","Dysthmia, enuresis","USA","7 to 17",12.1,3.1,12.1,2.8,12.1,NA,52.8,54.1,"mdd","21",NA,NA,NA,NA,NA,NA,NA
"68",68,"Wagner","2006",0,"Escitalopram","Placebo","CDRS",1,1,"clinician",54.5,NA,131,56.6,NA,133,NA,NA,NA,NA,NA,NA,-21.9,NA,129,-20.2,NA,132,"CDRS score ≤28",59,129,NA,50,132,NA,"post",8,"y","Anxiety disorders (e.g. GAD, panic disorder, social phobia, specific phobia)","USA","6 to 17",12.2,2.9,12.4,3,12.3,3,51.9,51.9,"mdd","25",NA,NA,NA,NA,NA,NA,NA
"69",69,"Wagner","2006",0,"Escitalopram","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",81,129,NA,69,132,NA,"post",8,"y","Anxiety disorders (e.g. GAD, panic disorder, social phobia, specific phobia)","USA","6 to 17",12.2,2.9,12.4,3,12.3,3,51.9,51.9,"mdd","25",NA,NA,NA,NA,NA,NA,NA
"70",70,"Atkinson","2018",0,"Desvenlafaxine (high dose)","Placebo","CDRS",1,1,"clinician",58.45,9.45,121,57.28,8.94,119,NA,NA,NA,NA,NA,NA,-24.4,12.1,121,-22.9,12,119,"missing",NA,NA,NA,NA,NA,NA,"post",8,"y","ADHD, self-injurious behaviour, insomnia","USA, Chile","7 to 17",12.87,3.01,13.15,2.68,NA,NA,62.81,50,"mdd","42",NA,NA,NA,NA,NA,NA,NA
"71",71,"Atkinson","2018",0,"Desvenlafaxine (high dose)","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",66,106,0.623,57,102,0.559,"post",8,"y","ADHD, self-injurious behaviour, insomnia","USA, Chile","7 to 17",12.87,3.01,13.15,2.68,NA,NA,62.81,50,"mdd","42",NA,NA,NA,NA,NA,NA,NA
"72",72,"Atkinson","2018",0,"Desvenlafaxine (low dose)","Placebo","CDRS",1,1,"clinician",58.52,9.18,122,57.28,8.94,119,NA,NA,NA,NA,NA,NA,-23.7,12.05,120,-22.9,12,119,"missing",NA,NA,NA,NA,NA,NA,"post",8,"y","ADHD, self-injurious behaviour, insomnia","USA, Chile","7 to 17",13.07,2.8,13.15,2.68,NA,NA,56.56,50,"mdd","42",NA,NA,NA,NA,NA,NA,NA
"73",73,"Atkinson","2018",0,"Desvenlafaxine (low dose)","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",59,105,0.562,57,102,0.559,"post",8,"y","ADHD, self-injurious behaviour, insomnia","USA, Chile","7 to 17",13.07,2.8,13.15,2.68,NA,NA,56.56,50,"mdd","42",NA,NA,NA,NA,NA,NA,NA
"74",74,"Durgam","2018",0,"Vilazodone (30mg)","Placebo","CDRS",1,1,"clinician",56.8,8.5,180,57.5,8.6,171,32.5,11.5,180,34,12.9,170,-24.2,12.07,180,-22.5,11.73,170,"CDRS ≥40% improvement from baseline",103,180,0.632,80,170,0.559,"post",8,"missing","missing","USA","12 to 17",14.6,1.6,14.9,1.7,15,NA,59.4,60.2,"mdd","52",NA,67,55,131,115,124,113
"75",75,"Durgam","2018",0,"Vilazodone (30mg)","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,2.2,1,180,2.4,1.1,170,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",112,180,0.622,92,170,0.541,"post",8,"missing","missing","USA","12 to 17",14.6,1.6,14.9,1.7,15,NA,59.4,60.2,"mdd","52",NA,NA,NA,NA,NA,NA,NA
"76",76,"Durgam","2018",0,"Vilazodone (15mg)","Placebo","CDRS",1,1,"clinician",57.8,8.7,175,57.5,8.6,171,33.8,12,174,34,12.9,170,-22.9,11.87,174,-22.5,11.73,170,"CDRS ≥40% improvement from baseline",83,174,0.561,80,170,0.559,"post",8,"missing","missing","USA","12 to 17",14.9,1.6,14.9,1.7,15,NA,58.9,60.2,"mdd","52",NA,55,56,126,116,105,94
"77",77,"Durgam","2018",0,"Vilazodone (15mg)","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,2.2,1.2,174,2.4,1.1,170,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",98,174,0.563,92,170,0.541,"post",8,"missing","missing","USA","12 to 17",14.9,1.6,14.9,1.7,15,NA,58.9,60.2,"mdd","52",NA,NA,NA,NA,NA,NA,NA
"78",78,"Lundbeck","2020",0,"Vortioxetine (20mg)","Placebo","CDRS",1,1,"clinician",62.5,9.8,159,60.6,9.1,153,NA,NA,NA,NA,NA,NA,-18.9,14.14,139,-18.2,14.05,137,"CDRS ≥50% improvement",60,139,0.432,49,137,0.358,"post",12,"y","ADHD, Insomnia, Anxiety disorder, GAD, Social Anxiety Disorder","International (Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Poland, Russia, Serbia, South Africa, Spain, Ukraine, UK, USA)","12 to 17",14.5,1.63,14.8,1.6,NA,NA,59.9,68.2,"mdd","124",NA,NA,NA,NA,NA,NA,NA
"79",79,"Lundbeck","2020",0,"Vortioxetine (20mg)","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,2.69,1.06,139,2.73,1.05,137,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,"post",12,"y","ADHD, Insomnia, Anxiety disorder, GAD, Social Anxiety Disorder","International (Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Poland, Russia, Serbia, South Africa, Spain, Ukraine, UK, USA)","12 to 17",14.5,1.63,14.8,1.6,NA,NA,59.9,68.2,"mdd","124",NA,NA,NA,NA,NA,NA,NA
"80",80,"Lundbeck","2020",0,"Vortioxetine (10mg)","Placebo","CDRS",1,1,"clinician",61.2,9.4,145,60.6,9.1,153,NA,NA,NA,NA,NA,NA,-17.1,14.59,126,-18.2,14.05,137,"CDRS ≥50% improvement",53,126,0.421,49,137,0.358,"post",12,"y","ADHD, Insomnia, Anxiety disorder, GAD, Social Anxiety Disorder","International (Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Poland, Russia, Serbia, South Africa, Spain, Ukraine, UK, USA)","12 to 17",14.8,1.66,14.8,1.6,NA,NA,63.3,68.2,"mdd","124",NA,NA,NA,NA,NA,NA,NA
"81",81,"Lundbeck","2020",0,"Vortioxetine (10mg)","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,2.81,1.12,126,2.73,1.05,137,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,"post",12,"y","ADHD, Insomnia, Anxiety disorder, GAD, Social Anxiety Disorder","International (Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Poland, Russia, Serbia, South Africa, Spain, Ukraine, UK, USA)","12 to 17",14.8,1.66,14.8,1.6,NA,NA,63.3,68.2,"mdd","124",NA,NA,NA,NA,NA,NA,NA
"82",82,"Lundbeck","2020",0,"Fluoxetine","Placebo","CDRS",1,1,"clinician",61.8,8.9,150,60.6,9.1,153,NA,NA,NA,NA,NA,NA,-22,14.05,137,-18.2,14.05,137,"CDRS ≥50% improvement",68,137,0.496,49,137,0.358,"post",12,"y","ADHD, Insomnia, Anxiety disorder, GAD, Social Anxiety Disorder","International (Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Poland, Russia, Serbia, South Africa, Spain, Ukraine, UK, USA)","12 to 17",14.8,1.6,14.8,1.6,NA,NA,67.3,68.2,"mdd","124",NA,NA,NA,NA,NA,NA,NA
"83",83,"Lundbeck","2020",0,"Fluoxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,2.5,1.05,137,2.73,1.05,137,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,"post",12,"y","ADHD, Insomnia, Anxiety disorder, GAD, Social Anxiety Disorder","International (Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Poland, Russia, Serbia, South Africa, Spain, Ukraine, UK, USA)","12 to 17",14.8,1.6,14.8,1.6,NA,NA,67.3,68.2,"mdd","124",NA,NA,NA,NA,NA,NA,NA
"84",84,"Findling","2020",0,"Vilazodone","Placebo","CDRS",1,1,"clinician",58.5,9.4,186,57.7,9.2,182,37.2,14.2,186,37.8,13.7,182,-20.7,13.6,186,-20.3,1,182,"CDRS ≥40% improvement from baseline",81,158,0.513,67,155,0.432,"post",8,"y","Learning disorders, ADHD, Communication disorders, oppositional defiant disorder, anxiety disorders","USA, Canada","7 to 17",13,2.9,13,2.9,13,NA,67.4,57,"mdd","60",NA,53,48,127,106,102,87
"85",85,"Findling","2020",0,"Vilazodone","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,2.5,0.1,186,2.5,0.1,182,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,"post",8,"y","Learning disorders, ADHD, Communication disorders, oppositional defiant disorder, anxiety disorders","USA, Canada","7 to 17",13,2.9,13,2.9,13,NA,67.4,57,"mdd","60",NA,NA,NA,NA,NA,NA,NA
"86",86,"Findling","2020",0,"Fluoxetine","Placebo","CDRS",1,1,"clinician",58.1,8.3,97,57.7,9.2,182,34.7,12.8,97,37.8,13.7,182,-22.71,12.8,97,-20.3,1,182,"CDRS ≥40% improvement from baseline",46,84,0.548,67,155,0.432,"post",8,"y","Learning disorders, ADHD, Communication disorders, oppositional defiant disorder, anxiety disorders","USA, Canada","7 to 17",13.2,2.8,13,2.9,13,NA,52.6,57,"mdd","60",NA,35,41,69,96,46,98
"87",87,"Findling","2020",0,"Fluoxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,NA,NA,NA,NA,2.4,0.1,97,2.5,0.1,182,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,"post",8,"y","Learning disorders, ADHD, Communication disorders, oppositional defiant disorder, anxiety disorders","USA, Canada","7 to 17",13.2,2.8,13,2.9,13,NA,52.6,57,"mdd","60",NA,NA,NA,NA,NA,NA,NA
"88",88,"Le Noury","2015",0,"Paroxetine","Placebo","HAM-D",1,1,"clinician",18.9,4.24,93,19,4.1,87,NA,NA,NA,NA,NA,NA,-10.7,7.68,90,-9.1,0.83,87,"HAM-D score <8 or ≥50% improvement",60,90,0.6667,48,87,0.552,"post",8,"y","Anxiety disorder, Oppositional Defiant Disorder, Conduct Disorder, ADHD","USA, Canada","12 to 18",14.8,1.6,15.1,1.6,NA,NA,60.3,52.6,"mdd","12",NA,NA,NA,NA,NA,NA,NA
"89",89,"Le Noury","2015",0,"Paroxetine","Placebo","K-SADS-L",0,0,"clinician",28.3,9.5,93,28.3,4.85,87,NA,NA,NA,NA,NA,NA,-11.4,7.65,83,-9.4,0.83,85,"NA",NA,NA,NA,NA,NA,NA,"post",8,"y","Anxiety disorder, Oppositional Defiant Disorder, Conduct Disorder, ADHD","USA, Canada","12 to 18",14.8,1.6,15.1,1.6,NA,NA,60.3,52.6,"mdd","12",NA,NA,NA,NA,NA,NA,NA
"90",90,"Le Noury","2015",0,"Imipramine","Placebo","HAM-D",1,1,"clinician",18.1,4.19,95,19,4.1,87,NA,NA,NA,NA,NA,NA,-9,7.85,94,-9.1,0.83,87,"HAM-D score ≤8 or ≥50% improvement",55,94,0.585,48,87,0.552,"post",8,"y","Anxiety disorder, Oppositional Defiant Disorder, Conduct Disorder, ADHD","USA, Canada","12 to 18",14.9,1.6,15.1,1.6,NA,NA,69.6,52.6,"mdd","12",NA,NA,NA,NA,NA,NA,NA
"91",91,"Le Noury","2015",0,"Imipramine","Placebo","K-SADS-L",0,0,"clinician",27.5,4.97,95,28.3,4.85,87,NA,NA,NA,NA,NA,NA,-9.5,7.69,88,-9.4,0.83,85,"NA",NA,NA,NA,NA,NA,NA,"post",8,"y","Anxiety disorder, Oppositional Defiant Disorder, Conduct Disorder, ADHD","USA, Canada","12 to 18",14.9,1.6,15.1,1.6,NA,NA,69.6,52.6,"mdd","12",NA,NA,NA,NA,NA,NA,NA
"92",92,"Weihs","2018",0,"Desvenlafaxine","Placebo","CDRS",1,1,"clinician",56.337,9.585,115,57.06,8.91,112,NA,NA,NA,NA,NA,NA,-22.6,12.547,115,-23.1,12.488,112,"missing",NA,NA,NA,NA,NA,NA,"post",8,"y","ADHD, non-suicidal inurious behaviour, insomnia, generalised anxiety disorder, oppositional defiant disorder","USA, Mexico","7 to 17",12.869,1.46,12.65,1.425,NA,NA,55.139,57.5,"mdd","43",NA,NA,NA,NA,NA,NA,NA
"93",93,"Weihs","2018",0,"Desvenlafaxine","Placebo","CGI-I",0,0,"clinician",NA,NA,115,NA,NA,112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",68,99,0.687,62,99,0.626,"post",8,"y","ADHD, non-suicidal inurious behaviour, insomnia, generalised anxiety disorder, oppositional defiant disorder","USA, Mexico","7 to 17",NA,NA,12.65,1.425,NA,NA,NA,57.5,"mdd","43",NA,NA,NA,NA,NA,NA,NA
"94",94,"Weihs","2018",0,"Fluoxetine","Placebo","CDRS",1,1,"clinician",56.256,8.34,112,57.06,8.91,112,NA,NA,NA,NA,NA,NA,-24.8,12.382,112,-23.1,12.488,112,"missing",NA,NA,NA,NA,NA,NA,"post",8,"y","ADHD, non-suicidal inurious behaviour, insomnia, generalised anxiety disorder, oppositional defiant disorder","USA, Mexico","7 to 17",12.65,1.479,12.65,1.425,NA,NA,50.74,57.5,"mdd","43",NA,NA,NA,NA,NA,NA,NA
"95",95,"Weihs","2018",0,"Fluoxetine","Placebo","CGI-I",0,0,"clinician",NA,NA,112,NA,NA,112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",79,101,0.782,62,99,0.626,"post",8,"y","ADHD, non-suicidal inurious behaviour, insomnia, generalised anxiety disorder, oppositional defiant disorder","USA, Mexico","7 to 17",NA,NA,12.65,1.425,NA,NA,NA,57.5,"mdd","43",NA,NA,NA,NA,NA,NA,NA
"96",96,"Forest","2020",0,"Levomilnacipran (40mg)","Placebo","CDRS",1,1,"clinician",61.8,NA,134,61.1,NA,140,NA,NA,115,NA,NA,118,-23.28,11.9,115,-22.9,11.84,118,"missing",NA,NA,NA,NA,NA,NA,"post",8,"n",NA,"USA, Puerto Rico","12 to 17",14.8,1.62,14.3,1.59,14.7,1.67,70.1,69.5,"mdd","49",NA,NA,NA,NA,NA,NA,NA
"97",97,"Forest","2020",0,"Levomilnacipran (80mg)","Placebo","CDRS",1,1,"clinician",59.4,NA,138,61.1,NA,140,NA,NA,110,NA,NA,118,-22.64,11.74,110,-22.9,11.84,118,"missing",NA,NA,NA,NA,NA,NA,"post",8,"n",NA,"USA, Puerto Rico","13 to 17",14.8,1.75,14.3,1.59,14.7,1.67,63,69.5,"mdd","49",NA,NA,NA,NA,NA,NA,NA
"98",98,"Forest","2020",0,"Fluoxetine","Placebo","CDRS",1,1,"clinician",61.5,NA,134,61.1,NA,140,NA,NA,112,NA,NA,118,-24.37,11.85,112,-22.9,11.84,118,"missing",NA,NA,NA,NA,NA,NA,"post",8,"n",NA,"USA, Puerto Rico","14 to 17",14.7,1.67,14.3,1.59,14.7,1.67,62.7,69.5,"mdd","49",NA,NA,NA,NA,NA,NA,NA
